The effect of pioglitazone and rosiglitazone on atherosclerotic and inflammatory markers in patients with metabolic syndrome: a prospective, randomized, open-label, crossover trial
Phase of Trial: Phase IV
Latest Information Update: 30 Jun 2011
At a glance
- Drugs Pioglitazone (Primary) ; Rosiglitazone (Primary)
- Indications Metabolic syndrome
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 30 Jun 2011 Last checked against ClinicalTrials.gov record.
- 26 Jun 2007 Status changed from recruiting to completed.